Press Releases

SEK 000s Q1 21/22 Q1 20/21 May-April 20/21 Net sales 381 340 2,077 Operating profit (loss) -12,238 -8,665 -40,181 Profit (loss) for the period -12,225 -8,374 -39,482 Earnings per share, after dilution -0.43 -0.36 -1.39 Significant events during the first quarter The PROMIX breast cancer study at Karolinska University Hospital has been published in the […]

Biovica, active in cancer diagnostics, today announced that a pre-recorded presentation with CEO Anders Rylander has been published.

Biovica, active in cancer diagnostics, today announced that Warren Cresswell has been appointed President Americas and will be part of the management team.

The shareholders of Biovica International AB, reg. no. 556774-6150, (the “Company”) are hereby invited to the annual general meeting on Tuesday 31 August 2021.

Annual report for the financial year 2020/2021 for Biovica International AB is published today on our website

Preparations for the launch of DiviTum®TKa

Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Wednesday 9 June from 14.00 to 16.30.

May 20, 2021 – Biovica, active in cancer diagnostics, today announces that DiviTumTKa shows prognostic and predictive capabilities in metastatic cutaneous melanoma patients undergoing immunotherapy. These results from a new study at Karolinska University Hospital will be presented at the upcoming ASCO annual meeting, June 4-8, 2021.

Biovica, active in cancer diagnostics, today announced that the company has strengthened the management team with Helle Fisker as new commercial manager and Joakim Arwidson as new quality and regulatory manager.

Biovica, active in cancer diagnostics, today announced that the results from a budget impact model of monitoring with DiviTum®TKa can give savings of up to three times the extra spend relative to current management. The results will be presented at the leading health economics and outcomes research conference, ISPOR 2021 in May.